Speaker illustration

Professor Sanjay Kaul

Cedars-Sinai Medical Centre, Los Angeles (United States of America)

The role of SGLT2 inhibitors in CV risk reduction in patients with type 2 diabetes

Event: ESC CONGRESS 2019

Topic: Diabetes and the Heart

Session: SGLT2 inhibitors in clinical cardiology: modern-day cardiovascular management in patients with type 2 diabetes

Thumbnail

ESC 365 is supported by

logo Novo Nordisk